U
CELGZ

UBS’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History

UBS’s Portfolio CELGZ Stock Details CELGZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$4K Buy
+1,290
New +$3.76K ﹤0.01% 9729
2014
Q2 		– Sell
-1,517
Closed -$4K – 11399
2014
Q1 		$4K Sell
1,517
-19,054
-93% -$57.6K ﹤0.01% 9785
2013
Q4 		$57K Buy
20,571
+20,284
+7,068% +$56.9K ﹤0.01% 6799
2013
Q3 		$2K Sell
287
-93
-24% -$717 ﹤0.01% 10088
2013
Q2 		$3K Buy
+380
New +$2.75K ﹤0.01% 9730

Other funds holding CELGZ

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
PC
Pomelo Capital New York $1.04B AUM 1.25% 1-Year Est. Return
WJA
Williams Jones & Associates New York $4.82B AUM 19.95% 1-Year Est. Return

UBS's CELGZ Position: Q3 2014 in Review

UBS opened a new position in Celgene Corporation Contingent Value Rights (CELGZ) in Q3 2014: 1,290 shares worth $4K. The stake represents ﹤0.01% of the portfolio and ranks #9729 among its holdings. This is a return to the name: UBS previously reported a position in CELGZ as recently as Q1 2014.

UBS first reported a position in CELGZ in Q2 2013 and has held it in 5 quarters since. The position peaked at $57K in Q4 2013. 23 funds tracked by Wall St. Rank hold CELGZ as of Q3 2014.

  • UBS held 1,290 shares of Celgene Corporation Contingent Value Rights worth $4K as of Q3 2014.
  • Celgene Corporation Contingent Value Rights was a new UBS position in Q3 2014.
  • Celgene Corporation Contingent Value Rights made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9729 holding.
  • UBS first reported a position in Celgene Corporation Contingent Value Rights in Q2 2013 and has held it in 5 quarters since.
  • UBS's Celgene Corporation Contingent Value Rights position peaked at $57K in Q4 2013.
  • 23 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.